Document is current

Article History

Received: 30 September 2024

Accepted: 10 March 2025

First Online: 18 March 2025

Declarations

:

: As this study was based on database research of data collected as part of routine care for quality control, no ethics approval was needed.

: Not applicable.

: KB reports research funding and receipt of study devices from Medtronic for the investigator-initiated CRISTAL study, receipt of study devices from Dexcom, received study medication of Novo Nordisk for the investigator-initiated SERENA study, received consulting fees from Astrazeneca and Lilly, and served on the speaker bureau for Novo Nordisk, AstraZeneca and Mundipharma. RD reports receiving consulting fees from Metagenics, Procter & Gamble Company and Janssen Pharmaceutics and served on the speaker bureau for Metagenics, Procter & Gamble Company and Janssen Pharmaceutics. AB reports research support for analyzing epidemiological data (2023-2024) from Novo Nordisk. CM2 serves or has served on the advisory panel for Novo Nordisk, Sanofi, Eli Lilly and Company, Novartis, Boehringer Ingelheim, Roche, Medtronic, Imcyse, Insulet, Biomea Fusion and Vertex. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for CM2 from Medtronic, Imcyse, Novo Nordisk, Sanofi and ActoBio Therapeutics; CM2 serves or has served on the speakers bureau for Novo Nordisk, Sanofi, Eli Lilly and Company, Medtronic and Boehringer Ingelheim. Financial compensation for these activities has been received by KU Leuven. CM2 is president of EASD. All external support of EASD is to be found on www.easd.org. All disclosures are unrelated to the present work.